Ampio Pharmaceuticals updates Optina dose finding study

Ampio Pharmaceuticals (AMPE +3.4%) reports interim results from a dose finding trial of Optina in DME.

Ultimately, the IDRC recommended the continuation of the trial as "it was determined that there was a treatment dosage that was demonstrating a potentially beneficial anatomic effect [and] there were no significant safety concerns."

Once the trial is complete, the company will immediately initiate an open label extension study using the determined optimum dose. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs